|
1
|
Nathan DM, Buse JB, Davidson MB,
Ferrannini E, Holman RR, Sherwin R and Zinman B; American Diabetes
Association, ; European Association for the Study of Diabetes, :
Medical management of hyperglycaemia in type 2 diabetes mellitus: A
consensus algorithm for the initiation and adjustment of therapy: A
consensus statement from the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetologia.
52:17–30. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goodwin PJ, Ligibel JA and Stambolic V:
Metformin in breast cancer: Time for action. J Clin Oncol.
27:3271–3273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sehdev A, Shih YC, Vekhter B, Bissonnette
MB, Olopade OI and Polite BN: Metformin for primary colorectal
cancer prevention in patients with diabetes: A case-control study
in a US population. Cancer. 121:1071–1078. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tseng CH: Metformin significantly reduces
incident prostate cancer risk in Taiwanese men with type 2 diabetes
mellitus. Eur J Cancer. 50:2831–2837. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El-Benhawy SA and El-Sheredy HG: Metformin
and survival in diabetic patients with breast cancer. J Egypt
Public Health Assoc. 89:148–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tseng CH: Metformin may reduce oral cancer
risk in patients with type 2 diabetes. Oncotarget. 7:2000–2008.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han G, Gong H, Wang Y, Guo S and Liu K:
AMPK/mTOR-mediated inhibition of survivin partly contributes to
metformin-induced apoptosis in human gastric cancer cell. Cancer
Biol Ther. 16:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim YI, Kim SY, Cho SJ, Park JH, Choi IJ,
Lee YJ, Lee EK, Kook MC, Kim CG, Ryu KW and Kim YW: Long-term
metformin use reduces gastric cancer risk in type 2 diabetics
without insulin treatment: A nationwide cohort study. Aliment
Pharmacol Ther. 39:854–863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan
M and Li D: Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clin Cancer Res.
18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D,
Xie J, Tao M and Mao Y: Metformin use is associated with better
survival of breast cancer patients with diabetes: A meta-analysis.
Oncol. 20:1236–1244. 2015. View Article : Google Scholar
|
|
13
|
Yamamoto H, Watanabe Y, Maehata T, Morita
R, Yoshida Y, Oikawa R, Ishigooka S, Ozawa S, Matsuo Y, Hosoya K,
et al: An updated review of gastric cancer in the next-generation
sequencing era: Insights from bench to bedside and vice versa.
World J Gastroenterol. 20:3927–3937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Durães C, Almeida GM, Seruca R, Oliveira C
and Carneiro F: Biomarkers for gastric cancer: Prognostic,
predictive or targets of therapy? Virchows Arch. 464:367–378. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kahn SE, Haffner SM, Viberti G, Herman WH,
Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR and Zinman B;
Diabetes Outcome Progression Trial (ADOPT) Study Group, :
Rosiglitazone decreases C-reactive protein to a greater extent
relative to glyburide and metformin over 4 years despite greater
weight gain: Observations from a Diabetes Outcome Progression Trial
(ADOPT). Diabetes Care. 33:177–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Home PD, Kahn SE, Jones NP, Noronha D,
Beck-Nielsen H and Viberti G; ADOPT Study Group, ; RECORD Steering
Committee, : Experience of malignancies with oral glucose-lowering
drugs in the randomised controlled ADOPT (A Diabetes Outcome
Progression Trial) and RECORD (Rosiglitazone Evaluated for
Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes)
clinical trials. Diabetologia. 53:1838–1845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Valent F: Diabetes mellitus and cancer of
the digestive organs: An Italian population-based cohort study. J
Diabetes Complications. 29:1056–1061. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ruiter R, Visser LE, van Herk-Sukel MP,
Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings
RM and Stricker BH: Lower risk of cancer in patients on metformin
in comparison with those on sulfonylurea derivatives: Results from
a large population-based follow-up study. Diabetes Care.
35:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee CK, Jung M, Jung I, Heo SJ, Jeong YH,
An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, et al: Cumulative
metformin use and its impact on survival in gastric cancer patients
after gastrectomy. Ann Surg. 263:96–102. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lo SF, Chang SN, Muo CH, Chen SY, Liao FY,
Dee SW, Chen PC and Sung FC: Modest increase in risk of specific
types of cancer types in type 2 diabetes mellitus patients. Int J
Cancer. 132:182–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang PH, Chen ZW, Lv D, Xu YY, Gu WL,
Zhang XH, Le YL, Zhu HH and Zhu YM: Increased risk of cancer in
patients with type 2 diabetes mellitus: A retrospective cohort
study in China. BMC Public Health. 12:5672012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeh HC, Platz EA, Wang NY, Visvanathan K,
Helzlsouer KJ and Brancati FL: A prospective study of the
associations between treated diabetes and cancer outcomes. Diabetes
Care. 35:113–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee MY, Lin KD, Hsiao PJ and Shin SJ: The
association of diabetes mellitus with liver, colon, lung, and
prostate cancer is independent of hypertension, hyperlipidemia, and
gout in Taiwanese patients. Metabolism. 61:242–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi Y and Hu FB: The global implications
of diabetes and cancer. Lancet. 383:1947–1948. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoon JM, Son KY, Eom CS, Durrance D and
Park SM: Pre-existing diabetes mellitus increases the risk of
gastric cancer: A meta-analysis. World J Gastroenterol. 19:936–945.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ikeda F, Doi Y, Yonemoto K, Ninomiya T,
Kubo M, Shikata K, Hata J, Tanizaki Y, Matsumoto T, Iida M and
Kiyohara Y: Hyperglycemia increases risk of gastric cancer posed by
Helicobacter pylori infection: A population-based cohort study.
Gastroenterology. 136:1234–1241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamagata H, Kiyohara Y, Nakamura S, Kubo
M, Tanizaki Y, Matsumoto T, Tanaka K, Kato I, Shirota T and Iida M:
Impact of fasting plasma glucose levels on gastric cancer incidence
in a general Japanese population: The Hisayama study. Diabetes
Care. 28:789–794. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Giovannucci E, Harlan DM, Archer MC,
Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and
Yee D: Diabetes and cancer: A consensus report. CA Cancer J Clin.
60:207–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Noto H, Goto A, Tsujimoto T, Osame K and
Noda M: Latest insights into the risk of cancer in diabetes. J
Diabetes Investig. 4:225–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stopsack KH, Ziehr DR, Rider JR and
Giovannucci EL: Metformin and prostate cancer mortality: A
meta-analysis. Cancer Causes Control. 27:105–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Belfiore A, Frasca F, Pandini G, Sciacca L
and Vigneri R: Insulin receptor isoforms and insulin
receptor/insulin-like growth factor receptor hybrids in physiology
and disease. Endoc Rev. 30:586–623. 2009. View Article : Google Scholar
|
|
34
|
Ikeda F and Kiyohara Y: Helicobacter
pylori infection and Hyperglycemia/Diabetes are associated with an
increased risk of gastric cancer. Gan To Kagaku Ryoho. 42:529–533.
2015.(In Japanese). PubMed/NCBI
|
|
35
|
Zhou Y, Wang Y, Wang S and Shen L:
Hyperglycemia promotes human gastric carcinoma progression via
aquaporin 3. Dig Dis Sci. 60:2338–2345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu L, Zhu J, Prokop LJ and Murad MH:
Pharmacologic therapy of diabetes and overall cancer risk and
mortality: A meta-analysis of 265 studies. Sci Rep. 5:101472015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thakkar B, Aronis KN, Vamvini MT, Shields
K and Mantzoros CS: Metformin and sulfonylureas in relation to
cancer risk in type II diabetes patients: A meta-analysis using
primary data of published studies. Metabolism. 62:922–934. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Soranna D, Scotti L, Zambon A, Bosetti C,
Grassi G, Catapano A, La Vecchia C, Mancia G and Corrao G: Cancer
risk associated with use of metformin and sulfonylurea in type 2
diabetes: A meta-analysis. Oncologist. 17:813–822. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: A
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sciarretta S, Volpe M and Sadoshima J:
Mammalian target of rapamycin signaling in cardiac physiology and
disease. Circ Res. 114:549–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pasello G, Urso L, Conte P and Favaretto
A: Effects of sulfonylureas on tumor growth: A review of the
literature. Oncologist. 18:1118–1125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu G, Fang W, Xia T, Chen Y, Gao Y, Jiao
X, Huang S, Wang J, Li Z and Xie K: Metformin potentiates rapamycin
and cisplatin in gastric cancer in mice. Oncotarget. 6:12748–12762.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dowling RJ, Niraula S, Chang MC, Done SJ,
Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ
and Stambolic V: Changes in insulin receptor signaling underlie
neoadjuvant metformin administration in breast cancer: A
prospective window of opportunity neoadjuvant study. Breast Cancer
Res. 17:322015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Crino PB, Nathanson KL and Henske EP: The
tuberous sclerosis complex. N Engl J Med. 355:1345–1356. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huang J and Manning BD: A complex
interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc
Trans. 37:217–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Qin L, Wang Z, Tao L and Wang Y: ER stress
negatively regulates AKT/TSC/mTOR pathway to enhance autophagy.
Autophagy. 6:239–247. 2014. View Article : Google Scholar
|
|
48
|
Zhou JY, Xu B and Li L: A new role for an
old drug: Metformin targets MicroRNAs in treating diabetes and
cancer. Drug Dev Res. 76:263–269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Monami M, Lamanna C, Balzi D, Marchionni N
and Mannucci E: Sulphonylureas and cancer: A case-control study.
Acta Diabetol. 46:279–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Núñez M, Medina V, Cricco G, Croci M,
Cocca C, Rivera E, Bergoc R and Martín G: Glibenclamide inhibits
cell growth by inducing G0/G1 arrest in the human breast cancer
cell line MDA-MB-231. BMC Pharmacol Toxicol. 14:62013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhanping W, Xiaoyu P, Na C, Shenglan W and
Bo W: Voltage-gated K+ channels are associated with cell
proliferation and cell cycle of ovarian cancer cell. Gynecol Oncol.
104:455–460. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Abdul M and Hoosein N: Voltage-gated
potassium ion channels in colon cancer. Oncol Rep. 9:961–964.
2002.PubMed/NCBI
|
|
54
|
Malhi H, Irani AN, Rajvanshi P, Suadicani
SO, Spray DC, McDonald TV and Gupta S: KATP channels regulate
mitogenically induced proliferation in primary rat hepatocytes and
human liver cell lines. Implications for liver growth control and
potential therapeutic targeting. J Biol Chem. 275:26050–26057.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bonnet S, Archer SL, Allalunis-Turner J,
Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta
L, Bonnet S, et al: A mitochondria-K+ channel axis is suppressed in
cancer and its normalization promotes apoptosis and inhibits cancer
growth. Cancer Cell. 11:37–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Felipe A, Vicente R, Villalonga N,
Roura-Ferrer M, Martínez-Mármol R, Solé L, Ferreres JC and Condom
E: Potassium channels: New targets in cancer therapy. Cancer Detect
Prev. 30:375–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Conti M: Targeting K+ channels for cancer
therapy. J Exp Ther Oncol. 4:161–166. 2004.PubMed/NCBI
|
|
58
|
Ardehali H and O'Rourke B: Mitochondrial
K(ATP) channels in cell survival and death. J Mol Cell Cardiol.
39:7–16. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong
AP, Ng VW, Luk AO, Ozaki R, Tong PC, et al: Use of sulphonylurea
and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
Diabetes Res Clin Pract. 90:343–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Elwood PC, Gallagher AM, Duthie GG, Mur LA
and Morgan G: Aspirin, salicylates, and cancer. Lancet.
373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jamshidinaeini Y, Akbari ME, Abdollahi M,
Ajami M and Davoodi SH: Vitamin D status and risk of breast cancer
in Iranian women: A case-control study. J Am Coll Nutr. 35:639–646.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Osmak M: Statins and cancer: Current and
future prospects. Cancer Lett. 324:1–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
